ArticleLeukemia2021
Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN).
Abstract readLetterMulticenter Study
In one paragraph
Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Trial
- Post-transplant outcomes in IgD multiple myeloma:a propensity score-matched analysis.Transplantation and cellular therapy · 2026Article
- Single-cell analysis unveils distinct transcriptional alterations and cellular origins in IgD multiple myeloma.Haematologica · 2026Article
- A Rare Case Report of Immunoglobulin D Subtype Multiple Myeloma Complicated With Hyperlipidemia.Case reports in hematology · 2026Article
- Uncommon Entities, Uncommon Challenges: A Review of Rare Plasma Cell Disorders.Hematology reports · 2025Review
- Analysis of clinical characteristics, treatment response, and prognosis among 67 patients with anaplastic multiple myeloma.World journal of surgical oncology · 2025Article
- Exploring secondary extramedullary myeloma disease: a five-predictor scoring system with spotlight on double-hit cytogenetics.BMC medicine · 2025Article
- Clinicopathologic predictors of renal response and survival in newly diagnosed multiple myeloma with renal injury: a retrospective study.Clinical and experimental medicine · 2025Article
- Dissecting the high-risk property of 1q gain/amplification in patients with newly diagnosed multiple myeloma.American journal of cancer research · 2025Article
- [BCMA chimeric antigen receptor T cells therapy re-treatment of a patient with recurrent/refractory IgD multiple myeloma: A case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Review
- Immunoglobulin D-Lambda Multiple Myeloma Initially Presenting in the Sphenoid Sinus, Orbital Apex, and Skull Base: A Systematic Review with a Case Report.Journal of neurological surgery reports · 2024Article
- A case of benign immunoglobulin D monoclonal gammopathy of undetermined significance with 26 years of follow-up.EJHaem · 2024Article
- [Analysis of efficacy and safety of BCMA chimeric antigen receptor T cells in the treatment of 5 patients with recurrent/refractory IgD multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- Plasma cell neoplasms and related entities-evolution in diagnosis and classification.Virchows Archiv : an international journal of pathology · 2023Review
- Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials.Blood advances · 2022Article
- Immunoglobulin D Multiple Myeloma: A Rare Variant.Cureus · 2022Article
- [IgD multiple myeloma mimicking free light chain myeloma complicated by factor X deficiency: a case report].The Pan African medical journal · 2022Article
- Renal insufficiency predicts worse prognosis in newly diagnosed IgD multiple myeloma patients.Frontiers in oncology · 2022Article
- Clinical characteristics and survival of patients with IgD multiple myeloma.Blood science (Baltimore, Md.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Jin Liu *Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, The Second Military Medical University, Shanghai, China.
Xiaoxia Hu *State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0002-2719-3805
Yanchun Jia *Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, The Second Military Medical University, Shanghai, China.
Jin LuPeking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
Jae Hoon LeeIncheon Regional Cancer Center, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.
Kihyun KimDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0002-5878-8895
Wenming ChenDepartment of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Aijun LiuDepartment of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Yang LiuPeking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
Qi ChenDepartment of Health Statistics, Second Military Medical University, Shanghai, China.
Chunyang ZhangDepartment of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, The Second Military Medical University, Shanghai, China.ORCID http://orcid.org/0000-0001-6794-5760
Cheolwon SuhDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0002-9178-4431
Min Kyoung KimDepartment of Internal Medicine, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu, Republic of Korea.
Fan ZhouDepartment of Hematology & Oncology, Jingan District Zhabei Central Hospital Shanghai, Shanghai, China.
Wee Joo ChngDepartment of Hematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore.
Shaji K KumarDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-5392-9284
Brian DurieCedars-Sinai Medical Center, Los Angeles, CA, USA.
Jian Hou *Department of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. houjian@medmail.com.cn.ORCID http://orcid.org/0000-0002-2813-5850
Weijun Fu *Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, The Second Military Medical University, Shanghai, China. fuweijun2010@hotmail.com.ORCID http://orcid.org/0000-0002-5908-0207
Juan Du *Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, The Second Military Medical University, Shanghai, China. juan_du@live.com.ORCID http://orcid.org/0000-0003-2538-4007
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAsiaFemaleFollow-Up StudiesHumansImmunoglobulin DMaleMiddle AgedMultiple MyelomaPrognosisRetrospective StudiesSurvival RateImmunoglobulin D
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.